Boehringer Ingelheim

Boy tests his blood sugar levels at home
#Boehringer Ingelheim #Eli Lilly #Paediatrics #Phase III trial #Type 2 diabetes

Positive Phase III trial data for SGLT2 inhibitor in type 2 diabetes

A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes.  The DINAMO Phase III clinical trial demonstrated a statistically significant reduction in HbA1c with empagliflozin compared with… Read More

#News

Lykke Hinsch Gylvin
#Boehringer Ingelheim #New appointment #Pharma #Pharmaceutical industry

Boehringer boosts pharma division with key appointment

Boehringer Ingelheim has appointed Lykke Hinsch Gylvin as Head of Medicine and Chief Medical Officer, effective November 1, 2022. Most recently, Gylvin served as Vice President, Global Medical Franchise Head, Neuroscience at Novartis. She brings more than 20 years of pharmaceutical experience, ranging from early-stage drug development to post-approval lifecycle… Read More

#Business & Investment #News

Bacteria
#Antimicrobial resistance (AMR) #Boehringer Ingelheim #Precision medicine

Joint venture launches to fight antimicrobial resistance  

A new joint-venture has been formed between Evotec, Boehringer Ingelheim and bioMérieux in a bid to fight antimicrobial resistance (AMR) through the development of new antimicrobials and diagnostics.  Aurobac Therapeutics SAS will combine the expertise of its three founding companies and utilise a precision approach in the… Read More

#News

#Boehringer Ingelheim #Clinical trial #Idiopathic pulmonary fibrosis

Boehringer Ingelheim reports positive data for lung therapy  

Boehringer Ingelheim’s investigational therapy for idiopathic pulmonary fibrosis (IPF) has shown positive data in a Phase II clinical trial, the company has announced.   The company is investigating its oral phosphodiesterase 4B (PDE4B) inhibitor (BI 1015550) as a potential treatment for people with IPF.   In a… Read More

#News